Nicholas Piramal has registered 12% growth in topline during 1HFY2000, even as its net profit has surged ahead registering a growth of 23%.
Nicholas Piramal Limited is one of the largest pharmaceutical companies in India, commanding a combined market share of 5%. The company has a strong presence in anti-bacterials, cardiovusculars, opthalmics, vitamins, biotek and antacids. It is the only Indian firm that is a part of the Massachusetts Institute of Technology's industrial liaison programme.
Profit before Tax
Profit after Tax
Net profit margins
The company's bottomline has benefited from the decline in debt service payments and the decline in the costs of production. This has, consequently, enabled the company to improve its net profit margins to 10.8% (9.9%).
Nicholas Piramal has joined the select rank of Indian pharmaceutical companies that have started pursuing research in a big way. The company has achieved success in developing an anti malarial molecule, which is likely to hit the market in early 2000. The transition of the Nicholas Piramal into a research based pharmaceutical company will help in improving its prospects in the post 2005 era when product patents begin to be recognised in India.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407